BRPI0808090A2 - Composto, composição farmacêutica, e, método in vivo para medir depósitos de amilóide em um paciente - Google Patents

Composto, composição farmacêutica, e, método in vivo para medir depósitos de amilóide em um paciente

Info

Publication number
BRPI0808090A2
BRPI0808090A2 BRPI0808090-9A2A BRPI0808090A BRPI0808090A2 BR PI0808090 A2 BRPI0808090 A2 BR PI0808090A2 BR PI0808090 A BRPI0808090 A BR PI0808090A BR PI0808090 A2 BRPI0808090 A2 BR PI0808090A2
Authority
BR
Brazil
Prior art keywords
amyloid deposits
patient
compound
pharmaceutical composition
measuring
Prior art date
Application number
BRPI0808090-9A2A
Other languages
English (en)
Inventor
Erwan Arzel
Britt-Marie Swahn
David Wensbo
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of BRPI0808090A2 publication Critical patent/BRPI0808090A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

COMPOSTO, COMPOSIÇÃO FARMACÊUTICA, E, MÉTODO IN VIVO PARA MEDIR DEPÓSITOS DE AMILÓIDE EM UM PACIENTE. A presente invenção diz respeito a novos derivados de indol asubstituídos por 2-heteroarila, seus precursores e usos terapêuticos de tais compostos, tendo a fórmula estrutural (Ia) abaixo: e ao seu sal farmaceuticamente aceitável, composições e métodos de uso. Além disso, a invenção diz respeito a novos derivados de indol substituídos por 2-heteroarila que são adequados para formar imagem de depósitos de amilóide em pacientes vivos, suas composições, métodos de uso e processos para fabricar tais compostos. Mas especificamente, a presente invenção diz respeito a um método de formar imagem de depósitos de amilóide em cérebro in vivo para permitir o diagnóstico antemortem do mal de Alzheimer como medir a eficácia clínica de agentes terapêuticos para o mal de Alzheimer.
BRPI0808090-9A2A 2007-03-06 2008-03-05 Composto, composição farmacêutica, e, método in vivo para medir depósitos de amilóide em um paciente BRPI0808090A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89315107P 2007-03-06 2007-03-06
PCT/SE2008/050242 WO2008108729A1 (en) 2007-03-06 2008-03-05 Novel 2-heteroaryl substituted indoles 695

Publications (1)

Publication Number Publication Date
BRPI0808090A2 true BRPI0808090A2 (pt) 2014-06-17

Family

ID=39738509

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0808090-9A2A BRPI0808090A2 (pt) 2007-03-06 2008-03-05 Composto, composição farmacêutica, e, método in vivo para medir depósitos de amilóide em um paciente

Country Status (11)

Country Link
US (1) US20100098631A1 (pt)
EP (1) EP2121655A4 (pt)
JP (1) JP2010520275A (pt)
KR (1) KR20090115954A (pt)
CN (1) CN101636395A (pt)
AU (1) AU2008221667A1 (pt)
BR (1) BRPI0808090A2 (pt)
CA (1) CA2680055A1 (pt)
MX (1) MX2009009113A (pt)
RU (1) RU2009133256A (pt)
WO (1) WO2008108729A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009260519A1 (en) 2008-05-30 2009-12-23 Merck Sharp & Dohme Corp. Novel substituted azabenzoxazoles
AR072297A1 (es) 2008-06-27 2010-08-18 Novartis Ag Derivados de indol-2-il-piridin-3-ilo, composicion farmaceutica que los comprende y su uso en medicamentos para el tratamiento de enfermedades mediadas por la sintasa aldosterona.
CA2737031A1 (en) * 2008-09-29 2010-04-01 Abbott Laboratories Indole and indoline derivatives and methods of use thereof
EP2501696B1 (en) 2009-10-15 2016-12-28 Guerbet Imaging agents and their use for the diagnostic in vivo of neurodegenerative diseases, notably alzheimer's disease and derivative diseases
CN114380731B (zh) * 2022-03-09 2024-07-02 台州学院 一种kcnq钾离子通道激动剂、药物组合物及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2274973T3 (es) * 2001-04-23 2007-06-01 The Trustees Of The University Of Pennsylvania Inhibidores de la agregacion de placas amiloides y agentes de obtencion de imagenes diagnosticas.
CA2438032C (en) * 2003-03-14 2013-05-07 University Of Pittsburgh Benzothiazole derivative compounds, compositions and uses
EP1893576A4 (en) * 2005-05-27 2010-03-17 Univ Kingston TREATMENT OF PROTEIN DISORDERING

Also Published As

Publication number Publication date
EP2121655A4 (en) 2010-09-22
JP2010520275A (ja) 2010-06-10
MX2009009113A (es) 2009-09-04
WO2008108729A1 (en) 2008-09-12
CA2680055A1 (en) 2008-09-12
US20100098631A1 (en) 2010-04-22
KR20090115954A (ko) 2009-11-10
AU2008221667A1 (en) 2008-09-12
CN101636395A (zh) 2010-01-27
RU2009133256A (ru) 2011-04-20
EP2121655A1 (en) 2009-11-25

Similar Documents

Publication Publication Date Title
ECSP088645A (es) Nuevos benzotiazoles sustituidos con heteroaril
UY30419A1 (es) Nuevos benzoxazoles heteroaril sustituidos
BRPI0808503B8 (pt) composto, uso de um composto, e, composição farmacêutica
CN111039939B (zh) 用作蛋白质聚集抑制剂的杂芳基酰胺
ES2962890T3 (es) Uso del cannabidiol en el tratamiento del complejo de esclerosis tuberosa
WO2009155017A3 (en) Novel substituted azabenzoxazoles
MX375282B (es) Pirrolo[2,3-c]piridinas como agentes de formacion de imagenes para ovillos neurofibrilares.
ES2584653T3 (es) Sonda para la obtención de imágenes de Tau
MX2009007487A (es) Derivados de imidazo[1,2-a]piridina substituidos de heteroarilo novedosos.
BR0113470A (pt) Composto de ligação amilóide, composição farmacêutica e métodos de sìntese de composto, de detecção in vivo de depósitos amilóides num indivìduo e em tecido humano ou animal, de quantificação de depósito amilóide em tecido de biópsia ou post-mortem e de distinção de um cérebro de doença de alzheimer de um cérebro normal
BR112014021634A8 (pt) inibidores de serina/treonina quinase,composições que os compreendem, seus usos e seus processos de preparação, e método de inibir a atividade da proteína quinase erk em uma célula
TW201444860A (zh) 脲嘧啶核苷衍生物、組合物及使用方法
TWI664169B (zh) 用於合成造影劑及其中間體之方法及裝置
WO2011052888A3 (ko) (3-플루오로-2-히드록시)프로필 작용기가 도입된 아릴 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 퇴행성 뇌질환의 진단 또는 치료용 약학적 조성물
BRPI0917147B8 (pt) composto ou sal deste, uso de um composto ou sal deste, e, processo para fabricar um composto
EA200801529A1 (ru) Кристаллические формы 1-бензоил-4-[2-[4-метокси-7-(3-метил-1h-1,2,4-1-ил)-1-[(фосфонокси)метил]-1h-пирроло[2,3-c]пиридин-3-ил]-1,2-диоксоэтил]пиперазина
ES2936833T3 (es) Tasimelteón para tratar síndrome de Smith-Magenis
WO2010051196A8 (en) Novel substituted azabenzoxazoles
MX2009009113A (es) Nuevos indoles 2-heteroaril sustituidos 695.
WO2017132263A1 (en) Phosphonate-drug conjugates
Hausner et al. Synthesis of 5-and 6-substituted 2-(4-dimethylaminophenyl)-1, 3-benzoxazoles and their in vitro and in vivo evaluation as imaging agents for amyloid plaque
ES2875058T3 (es) Uso de compuestos de fenoxipropilamina para tratar la depresión
JP2022046536A (ja) ビスホスホネートの骨格除去
MX2025009562A (es) Enlazadores de alfa-sinucleína y métodos de uso
WO2024186584A3 (en) Alpha-synuclein binders and methods of use

Legal Events

Date Code Title Description
B08L Patent application lapsed because of non payment of annual fee [chapter 8.12 patent gazette]

Free format text: REFERENTE AO NAO RECOLHIMENTO DAS 4A, 5A E 6A ANUIDADES.

B08I Publication cancelled [chapter 8.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 8.12 NA RPI NO 2277 DE 26/08/2014 POR TER SIDO INDEVIDA.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 4A, 5A, 6A, 7A, 8A, 9A, 10A, 11A E 12A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2602 DE 17-11-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.